JP2017531016A5 - - Google Patents

Info

Publication number

JP2017531016A5

JP2017531016A5 JP2017520427A JP2017520427A JP2017531016A5 JP 2017531016 A5 JP2017531016 A5 JP 2017531016A5 JP 2017520427 A JP2017520427 A JP 2017520427A JP 2017520427 A JP2017520427 A JP 2017520427A JP 2017531016 A5 JP2017531016 A5 JP 2017531016A5

Authority

JP

Japan

Prior art keywords

alkyl

optionally substituted

heterocycle

stereoisomer

salt

Prior art date

2015-10-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000000217 alkyl group Chemical group 0.000 claims 30
• 125000000623 heterocyclic group Chemical group 0.000 claims 17
• 150000001875 compounds Chemical class 0.000 claims 13
• 150000003839 salts Chemical class 0.000 claims 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims 7
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 6
• 229910052736 halogen Inorganic materials 0.000 claims 5
• 150000002367 halogens Chemical class 0.000 claims 5
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 5
• 201000010099 disease Diseases 0.000 claims 4
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 4
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 4
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
• MESFXNGUDNODTJ-UHFFFAOYSA-N 2h-thiazine 1,1-dioxide Chemical compound O=S1(=O)NC=CC=C1 MESFXNGUDNODTJ-UHFFFAOYSA-N 0.000 claims 3
• 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
• 125000002393 azetidinyl group Chemical group 0.000 claims 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
• 208000033679 diabetic kidney disease Diseases 0.000 claims 3
• 208000035475 disorder Diseases 0.000 claims 3
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
• 125000002757 morpholinyl group Chemical group 0.000 claims 3
• 125000000160 oxazolidinyl group Chemical group 0.000 claims 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
• 125000003386 piperidinyl group Chemical group 0.000 claims 3
• 208000011580 syndromic disease Diseases 0.000 claims 3
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
• -1 —OH 2 Chemical group 0.000 claims 3
• 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 2
• 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 2
• 206010018364 Glomerulonephritis Diseases 0.000 claims 2
• 206010020571 Hyperaldosteronism Diseases 0.000 claims 2
• 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
• 206010021263 IgA nephropathy Diseases 0.000 claims 2
• 125000000753 cycloalkyl group Chemical group 0.000 claims 2
• 206010061989 glomerulosclerosis Diseases 0.000 claims 2
• 230000005764 inhibitory process Effects 0.000 claims 2
• 208000017169 kidney disease Diseases 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
• 230000002861 ventricular Effects 0.000 claims 2
• 201000001320 Atherosclerosis Diseases 0.000 claims 1
• 208000024172 Cardiovascular disease Diseases 0.000 claims 1
• 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
• 206010058314 Dysplasia Diseases 0.000 claims 1
• 206010016654 Fibrosis Diseases 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
• 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
• 230000005856 abnormality Effects 0.000 claims 1
• 230000001919 adrenal effect Effects 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 230000004761 fibrosis Effects 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 125000001424 substituent group Chemical group 0.000 claims 1